7 United States sites
3 United Kingdom sites
2 Lebanon sites
4 to 18 Years
Phase 3
Interventional
All
Drug
Unknown
Open-label extension study of voxelotor for pediatric participants ages 4 to 18 years old
with Sickle Cell Disease who have participated in voxelotor clinical trials.
– Male or female participant with SCD, aged ≥ 4 to ≤ 18 years, who participated and
received study drug in a GBT-sponsored voxelotor pediatric clinical study
– Participant has provided written assent (both the consent of the participant’s legal
representative or legal guardian and the participant’s assent [where applicable] must
be obtained)
– Female participant who is breastfeeding or pregnant
– Participant withdrew consent from a GBT-sponsored voxelotor pediatric clinical study